Physician profile
Leon Weaver
NPI 1255323119
$1,835.11
in general payments reported to CMS, 2019-2025
20 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $146 · 2021: $390 · 2022: $264 · 2023: $292 · 2024: $267 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $267.35 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Pfizer INC. | $241.25 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $229.05 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $151.68 | 2020-2024 | Jornay Pm |
| Kaleo, INC. | $119.65 | 2019-2022 | |
| Cranial Technologies, INC | $111.16 | 2019-2023 | Doc Band |
| Sanofi Pasteur INC. | $105.21 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $102.08 | 2021-2023 | Qelbree |
| Corium, LLC | $86.36 | 2023-2024 | Azstarys |
| Sobi, INC | $66.95 | 2020-2023 | |
| Seqirus USA INC | $51.00 | 2023 | Flucelvax Quadrivalent |
| Vertical Pharmaceuticals, LLC | $50.69 | 2019-2024 | Relexxii |
| Ultragenyx Pharmaceutical INC. | $44.27 | 2021-2024 | Crysvita |
| Genentech USA, INC. | $40.77 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $39.74 | 2025 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $39.72 | 2019 | |
| Glaxosmithkline, LLC. | $31.22 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $28.73 | 2024-2025 | Zoryve |
| Adlon Therapeutics L.P. | $14.65 | 2019 | |
| Mission Pharmacal Company | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.